Leucid is progressing novel cart therapies that produce a better and more durable response.
Leucid Bio has raised $8.9M in total funding. The most recent round was Series A. The last funding was announced in February 2025.
Leucid Bio's investors include British Business Bank, Sofinnova Partners, Epidarex Capital, Vulpes Investment Management Pte Ltd, 2invest.
Leucid Bio is headquartered in London, United Kingdom.
Leucid is progressing novel cart therapies that produce a better and more durable response.
Leucid Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Leucid Bio — Funding & Investors." VCBacked, February 1, 2025, https://www.vcbacked.co/company/leucid-bio. Accessed October 8, 2026.
VCBacked. (2025). Leucid Bio — Funding & Investors. Retrieved October 8, 2026, from https://www.vcbacked.co/company/leucid-bio
{{cite web |title=Leucid Bio — Funding & Investors |url=https://www.vcbacked.co/company/leucid-bio |website=VCBacked |access-date=October 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated